Table 2. Study characteristics of reviewed random controlled trials.
RCT: Randomized controlled trial; TDT: Transdermal testosterone; US: United States; UK: United Kingdom
| Author/year | Study design | Location | # Cases/ control | Age means (case(s)/control) | Surgical/ Natural menopause | TDT dose (µg/d) | Oral estrogen use | Intervention period (weeks) |
| Braunstein G. et al. 2005 [1] | RCT | US | 328, 119 | 50.4, 49.6, 49.0, 48.5 | Surgical | 150, 300, 450 | Yes | 24 |
| Davis S. et al. 2008 [2] | RCT | US, Canada, Australia, Sweden, UK | 537, 277 | 54.1, 54.3, 54.4 | Natural | 150, 300 | No | 52 |
| Panay N. et al. 2010 [3] | RCT | UK, Australia, Germany, Canada | 130, 142 | 56.2, 57.0 | Natural | 300 | No | 24 |
| Shifren J. et al. 2006 [4] | RCT | US, Canada, Australia | 276, 273 | 53.9, 54.0 | Natural | 300 | Yes | 24 |
| Simon J. et al. 2005 [5] | RCT | US, Canada, Australia | 283, 279 | 49.2, 48.9 | Surgical | 300 | Yes | 24 |